AVANDARYL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AVANDARYL (AVANDARYL).
Combination of rosiglitazone (PPARγ agonist improving insulin sensitivity) and glimepiride (sulfonylurea stimulating insulin release from pancreatic beta cells).
| Metabolism | Rosiglitazone: primarily metabolized by CYP2C8, with minor involvement of CYP2C9. Glimepiride: metabolized by CYP2C9. |
| Excretion | Rosiglitazone: ~64% renal (as metabolites), ~23% fecal. Glimepiride: ~60% renal (60% of dose as metabolites, ~2% unchanged), ~40% fecal (as metabolites). |
| Half-life | Rosiglitazone: terminal half-life 3-4 hours (range 3-4.8 hours). Glimepiride: terminal half-life 5-8 hours (range 5-9 hours), with clinical duration of hypoglycemic effect up to 24 hours. |
| Protein binding | Rosiglitazone: 99.8% bound to albumin. Glimepiride: >99.5% bound to albumin. |
| Volume of Distribution | Rosiglitazone: Vd/F ~17.6 L (0.25 L/kg for 70 kg). Glimepiride: Vd/F ~0.12-0.16 L/kg. |
| Bioavailability | Rosiglitazone: absolute bioavailability ~99%. Glimepiride: absolute bioavailability 100%. |
| Onset of Action | Oral: Rosiglitazone onset of glycemic improvement within 2-4 weeks; glimepiride onset of insulin release ~30-60 minutes, maximal effect at 2-3 hours. |
| Duration of Action | Rosiglitazone: duration of glycemic control ~24 hours with once-daily dosing. Glimepiride: duration of hypoglycemic effect up to 24 hours, supporting once-daily dosing. |
Rosiglitazone 4 mg/glimepiride 2 mg orally once daily, titrated based on glycemic response; maximum dose: rosiglitazone 8 mg/glimepiride 4 mg per day.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in patients with eGFR <30 mL/min/1.73 m². For eGFR 30-60 mL/min/1.73 m², use with caution; no specific dose adjustment recommended. Avoid in dialysis. |
| Liver impairment | Contraindicated in Child-Pugh Class B or C. For Child-Pugh Class A, use with caution; no specific dose reduction recommended, but monitor liver function. |
| Pediatric use | Not approved for pediatric use (<18 years). Safety and efficacy not established. |
| Geriatric use | Start at lowest dose (rosiglitazone 4 mg/glimepiride 1 mg once daily) due to increased risk of hypoglycemia and fluid retention. Monitor renal function and edema. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AVANDARYL (AVANDARYL).
| Breastfeeding | Excretion into human milk unknown for both components. Rosiglitazone is excreted in rat milk; glimepiride is excreted in human milk. M/P ratio not available. Due to risk of neonatal hypoglycemia, avoid breastfeeding. Use only if clearly needed and monitor infant blood glucose. |
| Teratogenic Risk | Avandaryl (rosiglitazone/glimepiride) is a combination of a thiazolidinedione and a sulfonylurea. Rosiglitazone is pregnancy category C; animal studies show fetal harm, but no adequate human studies. Glimepiride is pregnancy category C; associated with neonatal hypoglycemia and macrosomia when used near term. First trimester: potential teratogenic effects unknown; avoid. Second and third trimesters: may cause neonatal hypoglycemia, hyperbilirubinemia, and weight gain. Not recommended during pregnancy. |
■ FDA Black Box Warning
May cause or exacerbate congestive heart failure. Rosiglitazone is associated with increased risk of cardiovascular events, particularly in patients with pre-existing heart disease.
| Serious Effects |
["Hypersensitivity to rosiglitazone, glimepiride, or any component.","Type 1 diabetes or diabetic ketoacidosis.","NYHA Class III/IV heart failure."]
| Precautions | ["Congestive heart failure risk; not recommended in patients with NYHA Class III/IV heart failure.","Cardiovascular risk; use with caution in patients with ischemic heart disease.","Hepatotoxicity; monitor liver enzymes.","Hypoglycemia risk due to glimepiride component.","Weight gain and fluid retention.","Increased risk of fractures (especially in women).","Macular edema reported."] |
| Food/Dietary | Take with food to reduce risk of hypoglycemia. Avoid excessive alcohol as it can cause unpredictable blood glucose changes. Grapefruit juice may increase rosiglitazone exposure; avoid concomitant intake. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose levels closely. Assess fetal growth via ultrasound due to risk of macrosomia. Monitor neonatal blood glucose for 24-48 hours after delivery if exposed near term. Assess for signs of hypoglycemia, jaundice, and weight abnormalities in the neonate. |
| Fertility Effects | Rosiglitazone may improve ovulation in women with polycystic ovary syndrome (PCOS) by reducing insulin resistance, potentially increasing fertility. Glimepiride may cause hypoglycemia, but no direct effects on fertility reported. Overall, the combination may affect ovulation and menstrual cycle regularity. |
| Clinical Pearls | Avandaryl is a fixed-dose combination of rosiglitazone (a thiazolidinedione) and glimepiride (a sulfonylurea). It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Due to cardiovascular risks associated with rosiglitazone, use is restricted; patients must have failed other therapies and be informed of risks. Monitor liver function tests before and during therapy; avoid use in patients with active liver disease or ALT >2.5x ULN. Drug can cause fluid retention and exacerbate heart failure; contraindicated in NYHA Class III/IV heart failure. Sulfonylurea component increases hypoglycemia risk, especially in elderly, renally impaired, or those skipping meals. |
| Patient Advice | Take exactly as prescribed with the first main meal of the day. · Do not skip meals and maintain a consistent carbohydrate intake. · Monitor blood glucose regularly as directed. · Report symptoms of hypoglycemia (shakiness, sweating, confusion) or hyperglycemia (excessive thirst, frequent urination). · Inform your doctor if you experience shortness of breath, rapid weight gain, or swelling (edema). · Avoid alcohol and over-the-counter medications without approval. · Notify your doctor before any surgical procedures or if pregnant/nursing. |